Dividend Medtech Giant Medtronic Is Built to Survive Any Market Crash

Eric Volkman, The Motley FoolSun, February 22, 2026 at 3:28 PM UTC

0

Key Points -

It isn't easy to find a healthcare company that regularly pays a generous dividend.

It's even harder to find one with an annual raise streak approaching 50 years.

10 stocks we like better than Medtronic ›

The terms "dividend" and "healthcare stock" usually aren't mentioned in the same sentence. They're almost unavoidable together when talking about Medtronic (NYSE: MDT), however. The company is not only a regular dividend payer, but also a frequent raiser, having lifted its distribution for 48 years in a row. But this is far from its only advantage.

The medical device king

Medtronic offers a wide range of products for treating various and sundry medical conditions. This makes the company's stock highly recession-resistant, as spending on essential procedures and care is often non-negotiable for people with health issues.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

Two people in white lab coats are looking at a computer display.

Image source: Getty Images.

The fundamentals tell the tale. Since 2000, Medtronic has seen declines in annual revenue only twice. And these weren't very dramatic -- the fiscal year 2020 fall of 5.4% was due to the onset of the COVID pandemic (in which medical facilities prioritized care for the disease), while unfavorable currency movements and supply chain issues pushed 2023 revenue down by 1.4%.

Over the years, management has been adept at growing the company into a major supplier to the most significant healthcare segments. All four of its current business units -- cardiovascular, medical-surgical, neuroscience, and diabetes -- generate strong revenue streams (although the relatively low-margin diabetes unit will soon be spun off).

In terms of profitability, Medtronic's bottom line can be somewhat up-and-down (due to factors like the company's pricey -- almost $43 billion -- acquisition of peer medical device company Covidien in 2015). Nevertheless, it has posted annual net income for more than 60 years in a row. That kind of record would be the envy of any business, large or small, in any industry.

What decidedly isn't up-and-down is the company's dividend. That 48-year raise streak is hard to beat, particularly in a sector that isn't exactly renowned for remunerating shareholders. In addition to being consistently on the rise, the distribution is generous -- it currently yields nearly 3%, more than double the average of all S&P 500 component stocks.

Underappreciated

Given Medtronic's ability to grow the top line and fund an ever-rising dividend, it might be surprising to learn that its stock has underperformed the benchmark S&P 500 index for years.

Advertisement

There are numerous reasons for this, not least management's habit of restructuring its business more frequently than most companies (I did say Medtronic was sprawling), and the attractiveness of healthcare companies with hotter and more compelling growth stories.

But there's something to be said for a steady business with a solid, nearly fortress-like position in its niche. And one with a future, too -- recently, for instance, Medtronic was granted clearance from the Food and Drug Administration (FDA) for its Hugo robotic-assisted surgery (RAS) system for use in certain types of urologic procedures.

In the coming years, I fully expect Medtronic to start outpacing the S&P 500, and the more it climbs, the more investors will notice and buy into it. I think it's wise to snap up shares of it before that occurs.

Should you buy stock in Medtronic right now?

Before you buy stock in Medtronic, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medtronic wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*

Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of February 22, 2026.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Medtronic. The Motley Fool has a disclosure policy.

Original Article on Source

Source: “AOL Money”